Jekyll2026-08-04T18:43:51+00:00https://tamador.org/feed.xmlTaMADORTargeted Mass Spectrometry Assays for Diabetes and Obesity Research - A multi-institutional consortium developing and disseminating quantitative protein assays for clinical research.US HUPO 2026 Evening Workshop: Targeting Diabetes and Obesity2026-02-22T00:00:00+00:002026-02-22T00:00:00+00:00https://tamador.org/meetings/workshops/2026/02/22/us-hupo-workshopThe TaMADOR consortium hosted a successful evening workshop at the 2026 US HUPO Conference in St. Louis, Missouri.

Workshop: Targeting Diabetes and Obesity: MS-based Assays that Inform Clinical Research Transferability

The workshop brought together experts from across the consortium to present advances in mass spectrometry-based assays relevant to diabetes and obesity research, with a focus on clinical research transferability.

The workshop featured three presentations:

  • Lorenz Nieves, PNNL
    • Interlaboratory validation of a glucagon and oxyntomodulin immuno-MRM workflow
  • Jun Qu, University of Buffalo
    • An Antibody Cocktail–Based Immunoaffinity–LC–MS Method for Ultra-Sensitive and Robust Quantification of Circulating Proinsulin Forms and C-peptide
  • Michael MacCoss, University of Washington
    • Using mass spectrometry to measure patient response to therapy

View the conference agenda

]]>Register Now for the 2026 TaMADOR Spring Symposium2026-02-11T00:00:00+00:002026-02-11T00:00:00+00:00https://tamador.org/meetings/2026/02/11/2026-spring-symposiumTargeted Mass Spectrometry Assays for Diabetes and Obesity Research (TaMADOR)

The 2026 TaMADOR Spring Symposium will be held on May 14th from 8:30 AM to 4:10 PM at UW Medicine, South Lake Union (Brotman Auditorium, D Building, 850 Republican St, Seattle, WA 98109).

Topics include:

  • History and purpose of TaMADOR
  • Single-islet proteomics and islet immune responses in T1D
  • Surrogate endpoint biomarkers for T1D interventions from a regulatory perspective
  • Interlaboratory validation of LC-MS/MS assays for glucagon and oxyntomodulin
  • Quantification of proinsulin and proglucagon processing products
  • Clinical applications of prohormone ratios in type 1 diabetes
  • Cross-laboratory validation of multiplexed LC-MS/MS assays
  • Panel discussion on C-peptide harmonization, clinical utility, and reimbursement

View the full agenda

Register for the symposium

]]>2025 TaMADOR Meeting at the NIH2025-03-04T00:00:00+00:002025-03-04T00:00:00+00:00https://tamador.org/meetings/2025/03/04/nih-tamador-meetingThe TaMADOR consortium held a symposium at the National Institutes of Health on March 4, 2025: Biomarkers and Mass Spectrometry–Based Assays in Type 1 Diabetes Clinical Research.

The precise and accurate quantification of proteins and peptides that are involved in diabetes pathogenesis will help facilitate research into disease mechanisms and ultimately improve the diagnosis, prognosis, and therapeutic management of patients with diabetes.

During this symposium, members of the TaMADOR consortium provided an overview of recent advances toward this goal, with a special focus on type 1 diabetes. Other speakers highlighted the importance of biomarkers and their harmonization in the study of diabetes and the care of patients with this important chronic disease.

View meeting agenda and information

NIDDK meeting page

]]>New Publications Page2024-04-25T00:00:00+00:002024-04-25T00:00:00+00:00https://tamador.org/publications/2024/04/25/new-publications-pageWe have launched a new page listing the publications from the four grants that have supported TaMADOR:

  • U01 DK137097 (University of Washington)
  • U01 DK137113 (Pacific Northwest National Laboratories)
  • U01 DK124020 (Pacific Northwest National Laboratories)
  • U01 DK124019 (Cedars-Sinai Medical Center)

View the Publications Page

]]>Register Now for the 2024 TaMADOR Symposium2024-03-28T00:00:00+00:002024-03-28T00:00:00+00:00https://tamador.org/meetings/2024/03/28/2024-tamador-symposiumTargeted Mass Spectrometry Assays for Diabetes and Obesity Research (TaMADOR)

The 2024 TaMADOR Symposium will be held on May 6th from 8am to 4pm at UW Medicine, South Lake Union (Brotman Auditorium, D Building, 850 Republican St, Seattle, WA).

Topics include:

  • The TaMADOR Consortium: Interlaboratory Transfer of a Combined Antibody-free Insulin/C-peptide Assay
  • Preparing for the Interlaboratory Transfer of a Novel Assay to Measure Glucagon and Oxyntomodulin
  • LC-MS Assays for Specific Prohormone Proteoforms (Insulin and IAPP) Relevant to Type 1 Diabetes
  • Progress Toward a Proteolysis-peptide Immunoaffinity Enrichment-LC-MS/MS Assay for Proinsulin
  • Hemoglobin A1c as a Clinical Biomarker
  • LC-MS Assays for Obesity Biomarkers
  • Using Mass Spectrometry for Monitoring Patient Response to Therapy

Register for the symposium

]]>Multiplexed Quantification of Insulin and C-peptide by LC-MS/MS Without Antibodies2023-09-06T00:00:00+00:002023-09-06T00:00:00+00:00https://tamador.org/publications/assays/2023/09/06/insulin-cpeptide-assayThe Hoofnagle lab has developed an LC-MS/MS assay to measure insulin and C-peptide without the use of antibodies.

Read the publication in Journal of Mass Spectrometry and Advances in the Clinical Lab

The measurement of insulin and C-peptide provides a valuable tool for the clinical evaluation of hypoglycemia. In research, these biomarkers are used together to better understand hyperinsulinemia, hepatic insulin clearance, and beta cell function.

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is an attractive approach for the analysis of insulin and C-peptide because the platform is specific, can avoid certain limitations of immunoassays, and can be multiplexed.

Previously described LC-MS/MS methods for the simultaneous quantification of insulin and C-peptide measure the intact analytes and most have relied on immunoaffinity enrichment. These approaches can be limited in terms of sensitivity and interference from auto-antibodies.

We have developed a novel method that does not require antibodies and uses proteolytic digestion to yield readily ionizable proteotypic peptides that enables the sensitive, specific, and simultaneous quantitation of insulin and C-peptide.

]]>UW and PNNL Funded to Develop Assays for Type 1 Diabetes2023-09-06T00:00:00+00:002023-09-06T00:00:00+00:00https://tamador.org/funding/news/2023/09/06/uw-pnnl-t1d-fundingThe TaMADOR program was funded with cooperative agreements between the NIDDK and consortium institutions a few years ago, and will now continue with emphasis on the development of assays of importance in type 1 diabetes clinical research.

See the NIH Request for Applications (RFA-DK-21-031).

The Principal Investigators leading this effort on type 1 diabetes are:

  • Dr. Andrew Hoofnagle (University of Washington, Seattle)
  • Dr. Michael MacCoss (University of Washington, Seattle)
  • Dr. Jun Qu (University at Buffalo)
  • Dr. Weijun Qian (PNNL)

Within the RFA we indicated a list of potential targets that the group could be working on, including:

  • Glucagon and other pro-glucagon derived peptides
  • C-peptide
  • Insulin
  • Pro-insulin
  • Glycated CD59
  • Islet Amyloid Polypeptide (IAPP)
  • Chromogranin A (CgA)
  • Chromogranin B (CgB)

We are looking forward to advisory group and community feedback for determining consortium priorities.

]]>2022 TaMADOR Meeting in Bethesda2022-10-27T00:00:00+00:002022-10-27T00:00:00+00:00https://tamador.org/meetings/2022/10/27/bethesda-meetingThe TaMADOR consortium met in Bethesda, MD on December 1, 2022 for a symposium on advances in multiplex quantification of protein/peptide hormones and biomarkers involved in obesity and diabetes.

The meeting brought together consortium members to share progress on assay development, validation, and implementation across the participating institutions.

View meeting details and agenda

]]>MSACL Workshop on the Development, Validation, and Implementation of Obesity and Diabetes Assays2021-06-02T00:00:00+00:002021-06-02T00:00:00+00:00https://tamador.org/meetings/workshops/2021/06/02/msacl-workshopThe TaMADOR consortium held a virtual workshop on June 3, 2021 at the MSACL (Mass Spectrometry: Applications to the Clinical Lab) conference.

This workshop provided an introduction to the TaMADOR program and facilitated discussion of mass spectrometry assays for the obesity and diabetes research community.

The workshop focused on:

  • Development of targeted MS assays for diabetes and obesity biomarkers
  • Validation strategies for clinical research applications
  • Implementation and dissemination of assays across laboratories

This event helped establish connections with the broader clinical mass spectrometry community and gather feedback on assay development priorities.

]]>Announcing TaMADOR: A Collaborative Working Group for Targeted Mass Spectrometry Assays2020-05-08T00:00:00+00:002020-05-08T00:00:00+00:00https://tamador.org/news/2020/05/08/announcing-tamadorTwo NIDDK programs, one focused on Type 1 Diabetes and one focused on Obesity, are working together to develop and share quantitative protein assays.

  • Type 1 Diabetes: Andy Hoofnagle’s lab at the University of Washington
  • Obesity: Jenny Van Eyk’s and Wei-Jun Qian’s labs at Cedars-Sinai and PNNL respectively

To leverage each other’s capabilities and strengths we have formed a working group that we call TaMADOR (Targeted Mass Spectrometry Assays for Diabetes and Obesity Research).

NIH Funding Announcements

]]>